

Pharma in brief - Canada

Health Canada releases Draft Guidance Document – Drug Facts Table for Non-prescription Drugs for consultation

Summary

On February 20, 2017, Health Canada released the Draft Guidance Document – Drug Facts Table for Non-prescription Drugs for comment. Interested stakeholders, including industry, consumers and healthcare professionals, may provide comments on the draft guidance document by email to nnhpd_consultation_dpsnso@hc-sc.gc.ca. The consultation period is open until **April 21, 2017**.

Overview

As part of Health Canada's Plain Language Labelling Initiative (reported [here](#)), Health Canada released the Draft Guidance Document: Drug Facts Table for Non-prescription Drugs, which contains examples of drug facts tables for various active ingredients. The examples are intended to show the application of the specific formatting requirements for drug facts tables as set out in the [Guidance Document: Good Label and Package Practices Guide for Non-prescription Drugs and Natural Health Products \(GLPPG\)](#).

As part of the Plain Language Labelling Initiative, Health Canada will require that any new drug identification number (**DIN**) applications or supplemental new drug submissions submitted on and after June 13, 2017, comply with the drug facts table requirements set out in the GLPPG. In addition, currently marketed products must comply with the drug facts table requirements at the production level by June 20, 2019, and at the retail level by June 30, 2021.

The Plain Language Labelling Initiative imposes significant new obligations on industry. Interested stakeholders should consider whether the Draft Guidance – Drug Facts Table for Non-Prescription Drugs appropriately addresses the formatting requirements as set out in the GLPPG.

Link:

[Draft Guidance Document: Drug Facts Table for Non-prescription Drugs](#)

For more information, please contact your IP/Life sciences or healthcare practice professional at Norton Rose Fulbright Canada LLP.

For a complete list of our IP team, [click here](#). For a complete list of our Life sciences and healthcare team, [click here](#).

Norton Rose Fulbright Canada LLP, Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright South Africa Inc and Norton Rose Fulbright US LLP are separate legal entities and all of them are members of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal services to clients.

References to "Norton Rose Fulbright", "the law firm", and "legal practice" are to one or more of the Norton Rose Fulbright members or to one of their respective affiliates (together "Norton Rose Fulbright entity/entities"). No individual who is a member, partner, shareholder, director, employee or consultant of, in or to any Norton Rose Fulbright entity (whether or not such individual is described as a "partner") accepts or assumes responsibility, or has any liability, to any person in respect of this communication. Any reference to a partner or director is to a member, employee or consultant with equivalent standing and qualifications of the relevant Norton Rose Fulbright entity.

The purpose of this communication is to provide general information of a legal nature. It does not contain a full analysis of the law nor does it constitute an opinion of any Norton Rose Fulbright entity on the points of law discussed. You must take specific legal advice on any particular matter which concerns you. If you require any advice or further information, please speak to your usual contact at Norton Rose Fulbright.